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Poster Session II S365and conjunctiva with T-cells leading to inflammatory-mediated dys-
function of the secretory epithelium is thought to contribute to its
development.
Ocular symptomsmay be the presenting feature ofGVHD, occur-
ring in the absence of other systemic manifestations of GVHD. The
initial subclinical symptoms commonly reported by patients include
excessive tearing, nonspecific discomfort or sense of foreign object,
and mild photophobia.
Keratoconjunctivitis sicca (KCS) characterized as dryness of the
conjunctiva and cornea is the most common clinical manifestation
of ocular GVHD. KCS may lead to corneal erosions and filaments
causing significant pain and photophobia. Severe KCS with corneal
ulceration may lead to loss of vision. Once lacrimal gland scarring
occurs, the damage caused by ocular GVHD is irreversible and can
profoundly impact the patient’s quality of life.
Recognition of the early signs and symptoms of ocular GVHD
leads to appropriate diagnostic testing, timely treatment and reduc-
tion in morbidity.
The purpose of this presentation is to provide a clinical overview
of ocular GVHD to hematopoietic stem cell transplant nurses, high-
lighting their role in identifying the often subtle signs and symptoms
of its initial presentation. Also included, will be an overview of the
diagnostic evaluation, treatment options and common nursing inter-
ventions specific to the nursing management and educational needs
of these patients.593
STEM CELL COLLECTION: A TALE OF TWO UNITS. A UK/US COMPARISON
Baker, J. Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Working in a JACIE accredited transplant center, we apheresis
nurses strive to achieve and manage a nurse-led,evidence based,col-
laborative service providing exemplary patient and donor care in the
collection of peripheral hematopoietic stem cells for autologous and
sibling transplant.
There is perhaps a general assumption that in this specialist area
there are more similarities than differences with regards to practice
both nationally and internationally.
This presentation is an overview of two apheresis units looking at
some core elements of patient management.One is my own unit at
the Royal Marsden Hospital, a JACIE accredited, respected cancer
hospital in the UK. The other is a consistently highly ranked
FACT accredited academic medical center,the Cleveland Clinic in
Ohio,US.
The following discussion highlights some significant differences
and proves that across the pond we are divided by more than just
a common language!
It will be interesting to ascertain if colleagues in the audience rec-
ognise and identify with current practice at my institution or that of
the US.
Noteworthy areas for comparison are nurse education and train-
ing; nurse-led vs. medical led service;peripheral vs. central intrave-
nous access; management of citrate toxicity; donor care; apheresis
procedures, and CD34 target yields.
There may be a more medicalised approach to stem cell collection
in this particular US unit with perhaps increased economic and
healthcare implications.594
NEW HOPE: SUPPORTIVE NURSING CARE FOR MULTIPLE SCLEROSIS
PATIENTS RECEIVING AN AUTOLOGOUS TRANSPLANT
Rochester, J.M. Seattle Cancer Care Alliance, Seattle, WA
MS is an immune mediated disease of the central nervous system
causing nerve demyelination and progressive degeneration.
Common symptoms include: muscle strength changes, visual com-
plications and sensory alterations. Bladder, bowel and sexual dys-
function are common, along with speech and swallowing
symptoms, heat sensitivity, cognitive impairment and fatigue.
Purpose:The FredHutchinson Cancer Research Center (FHCRC)
is participating in an NCI phase II multi-center trial offering high-
dose immunosuppressive therapy involving rescue with autologousCD 34+ selected hematopoietic stem cells for MS patients. We are
utilizing therapy used in treating malignancy to also treat an autoim-
mune disease. It is hypothesized that this intensive therapy will arrest
disease activity in these individuals. The nursing care for these pa-
tients is crucial for a successful outcome.
Interventions:This study opened in 2006 and 24 patients have been
transplanted with five year followup. Multiple Sclerosis is a complex
disease associated with various physical, emotional and cognitive im-
pairments. Fatigue is an on-going problem and heat exacerbates
symptoms. Bladder dysfunction may require intervention to control
urinary urgency and increased risk of urinary tract infections.
Evaluation: Caring for MS patients contrasted with cancer patients
can be challenging for the transplant nurse. Teaching and nursing
care must be designed for the special needs of these patients. Toxic-
ities of chemotherapy and immunosuppression present new chal-
lenges for the patient. Fevers can lead to significant dysfunction.
Education about fall risks is important for safety. Giving patients
instructions in writing can be helpful because of possible cognitive
impairment.
Discussion: Nurses are challenged to go beyond traditional trans-
plant expertise for education of family members andMS patients go-
ing through a transplant. Toxicities from transplant include: MS
flares with fever and GCSF use during mobilization, increased sus-
ceptibility for EBV post transplant lymphoproliferative disorder,
engraftment syndrome andCMV.Nurses are now in a position to in-
tegrate the concept of hope into the clinical management of a disease
that was thought to be hopeless.595
CHALLENGES IN DIAGNOSIS AND TREATMENT OF HHV6 DURING
ALLOGENIC STEM CELL TRANSPLANTATION
Zanter, A.K. Duke University Hospital, Durham, NC
Human herpesvirus 6 (HHV-6) is a common virus that when reac-
tivated in patients undergoing allogenic stem cell transplant can cre-
ate many challenges in their care and treatment. Most commonly,
HHV-6 is known to cause suppression of hematopoiesis resulting
in graft rejection and graft failure. Reactivation has been noted to oc-
cur between 2-4 weeks after transplant. The incidence of HHV-6 in-
fection is known to be higher in patients undergoing allogenic
transplant, specifically among patients with unrelated or mis-
matched donors due to the increased level of immunosuppression
during and after their conditioning regimens to prevent graft versus
host disease.
Among our allogenic transplants from January 2009 until the pres-
ent, approximately 27 patients have developed HHV6 viremia. This
has been challenging as there are no clear guidelines for monitoring
levels and treatment initiation guidelines. This year our program
routinely sentHHV-6 PCRblood samples weekly during the perien-
graftment period on all patients who received cord blood and non-
myeloablative allografts.We consider initiating treatmentwhen viral
loads are .200 copies.
The treatment of HHV-6 relies on the use of one of two anti-viral
medications, foscarnet and ganciclovir. Our program uses an induc-
tion regimen of twice daily treatment for two weeks followed by
a maintenance regimen of once daily for two weeks. The viral
PCR is monitored weekly and treatment is discontinued after 4
weeks of therapy if the virus in no longer detected.Weekly monitor-
ing must be continued among these patients to monitor for re-acti-
vation. Our experience highlights the need for further research into
the treatment of HHV-6.596
TRANSFORMING CARE AT THE BEDSIDE WITH AN EVIDENCED BASED
SKILLS DAY APPROACH
Munaretto, M., Anderson, L., Komoto, B., Hattori, Y. City of Hope,
Duarte, CA
Background and Significance: Transforming care at the bedside
was the focus of a 2003 Robert Wood Johnson Foundation grant.
A successful pilot at the University of Pittsburgh Medical Center,
Shadyside, demonstrated improved patient care utilizing work re-de-
sign by front line staff to: 1) center improvement around staff or
